Orbimed Advisors LLC Apellis Pharmaceuticals, Inc. Transaction History

Orbimed Advisors LLC

$2.93 Billion
Q3 2025

A detailed history of Orbimed Advisors LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 2,323,368 shares of APLS stock, worth $47.2 Million. This represents 1.79% of its overall portfolio holdings.

Number of Shares

2,323,368

Previous 50,000 4546.74%

Holding current value

$47.2 Million

Previous $865,000 5978.27%

% of portfolio

1.79%

Previous 0.03%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$17.42 - $28.65 $14.7 Million - $24.1 Million	841,068 Added 56.74%	2,323,368 $52.6 Million
Q2 2025 Aug 14, 2025	BUY	$16.36 - $23.0 $818,000 - $1.15 Million	50,000 Added 3.49%	1,482,300 $25.7 Million
Q1 2025 May 15, 2025	BUY	$21.87 - $34.63 $31.3 Million - $49.6 Million	1,432,300 New	1,432,300 $31.3 Million
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $934,416 - $1.33 Million	-32,400 Reduced 2.49%	1,270,400 $36.6 Million
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $190,350 - $298,550	5,000 Added 0.39%	1,302,800 $50 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $20.8 Million - $27.2 Million	375,600 Added 40.73%	1,297,800 $76.3 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $12.6 Million - $21.9 Million	-338,300 Reduced 26.84%	922,200 $55.2 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $8.28 Million - $31.3 Million	350,300 Added 38.49%	1,260,500 $47.9 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $42.4 Million - $60.9 Million	910,200 New	910,200 $60 Million
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $1.25 Million - $1.94 Million	-50,485 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $904,186 - $2.24 Million	50,485 New	50,485 $1.35 Million
Q4 2019 Feb 14, 2020	SELL	$22.1 - $30.8 $13.8 Million - $19.2 Million	-623,859 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$24.09 - $32.18 $28.9 Million - $38.6 Million	-1,199,841 Reduced 65.79%	623,859 $15 Million
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $1.11 Million - $1.56 Million	61,400 Added 3.48%	1,823,700 $46.2 Million
Q1 2019 May 15, 2019	BUY	$12.81 - $19.82 $18.4 Million - $28.4 Million	1,435,300 Added 438.93%	1,762,300 $34.4 Million
Q4 2018 Feb 14, 2019	BUY	$11.47 - $18.71 $3.75 Million - $6.12 Million	327,000 New	327,000 $4.31 Million

Others Institutions Holding APLS

# of Institutions

329

Shares Held

124M

Call Options Held

4.15M

Put Options Held

769K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.23B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Account

Orbimed Advisors LLC Apellis Pharmaceuticals, Inc. Transaction History